Cytodyn Inc (CYDY) financial statements (2020 and earlier)

Company profile

Business Address 1111 MAIN STREET, SUITE 660
VANCOUVER, WA 98660
State of Incorp. DE
Fiscal Year End May 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

8/31/2019
TTM
5/31/2019
5/31/2018
5/31/2017
5/31/2016
5/31/2015
5/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments23121015
Cash and cash equivalents23121015
Restricted cash and investments 1     
Prepaid expense0000000
Deferred costs      0
Other undisclosed current assets122421 
Total current assets:35361125
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment0000000
Intangible assets, net (including goodwill)151522233
Intangible assets, net (excluding goodwill)151522233
Total noncurrent assets:151622233
TOTAL ASSETS:1821581458
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1418174251
Accounts payable1216164251
Accrued liabilities  0   0
Employee-related liabilities121    
Interest and dividends payable00     
Debt54 1 (0) 
Estimated litigation liability      0
Other undisclosed current liabilities4501160
Total current liabilities:23271764112
Noncurrent Liabilities
Long-term debt and lease obligation00    2
Long-term debt, excluding current maturities00    2
Operating lease, liability0
Liabilities, other than long-term debt2213 2 
Derivative instruments and hedges, liabilities2213 2 
Other undisclosed noncurrent liabilities     3 
Total noncurrent liabilities:2313 52
Total liabilities:25301894155
Stockholders' equity
Stockholders' equity attributable to parent, including:(7)(9)(13)(1)10(11)4
Preferred stock  00000
Common stock000003630
Treasury stock, value(0)(0)(0)    
Additional paid in capital2382201601221072520
Accumulated deficit(246)(229)(173)(123)(97)(72)(46)
Other undisclosed stockholders' equity attributable to parent00    (0)
Total stockholders' equity:(7)(9)(13)(1)10(11)4
TOTAL LIABILITIES AND EQUITY:1821581458

Income statement (P&L) ($ in millions)

8/31/2019
TTM
5/31/2019
5/31/2018
5/31/2017
5/31/2016
5/31/2015
5/31/2014
Operating expenses(55)(56)(46)(27)(21)(20)(8)
Operating loss:(55)(56)(46)(27)(21)(20)(8)
Nonoperating income3222100
Investment income, nonoperating32221(1)0
Debt instrument, convertible, beneficial conversion feature     1 
Interest and debt expense(9)(5)(6)(1)(5)(6)(5)
Other undisclosed income from continuing operations before equity method investments, income taxes     00
Loss from continuing operations before income taxes:(61)(59)(50)(26)(26)(25)(12)
Income tax expense (benefit)(3)3     
Net loss:(64)(56)(50)(26)(26)(25)(12)
Other undisclosed net income attributable to parent6      
Net loss available to common stockholders, diluted:(58)(56)(50)(26)(26)(25)(12)

Comprehensive Income ($ in millions)

8/31/2019
TTM
5/31/2019
5/31/2018
5/31/2017
5/31/2016
5/31/2015
5/31/2014
Net loss:(64)(56)(50)(26)(26)(25)(12)
Comprehensive loss, net of tax, attributable to parent:(64)(56)(50)(26)(26)(25)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: